WHEA:LSE:LSE-SPDR® MSCI World Health Care UCITS ETF (USD)

ETF | Others |

Last Closing

USD 58.87

Change

-0.30 (-0.51)%

Market Cap

USD 0.59B

Volume

3.22K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R15:LSE SoftBank Group Corp.

+122.01 (+1.57%)

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

+71.00 (+0.93%)

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+4.95 (+0.57%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.06 (+0.46%)

USD 617.54B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.03 (+0.15%)

USD 617.54B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

-7.25 (-0.36%)

USD 348.03B
0QZK:LSE Coca-Cola Co.

+0.70 (+1.15%)

USD 266.08B
0QZO:LSE 0QZO

-1.40 (-1.24%)

USD 258.54B

ETFs Containing WHEA:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.98% 50% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.98% 49% F 53% F
Trailing 12 Months  
Capital Gain 2.72% 42% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.72% 40% F 51% F
Trailing 5 Years  
Capital Gain 63.60% 82% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.60% 80% B- 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 9.96% 72% C 73% C
Dividend Return 9.96% 71% C- 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.36% 66% D+ 79% B-
Risk Adjusted Return 96.09% 97% N/A 98% N/A
Market Capitalization 0.59B 72% C 62% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike